CN106692156A - Chinese and Western medicine composition for treating cirrhotic ascites - Google Patents
Chinese and Western medicine composition for treating cirrhotic ascites Download PDFInfo
- Publication number
- CN106692156A CN106692156A CN201611235217.6A CN201611235217A CN106692156A CN 106692156 A CN106692156 A CN 106692156A CN 201611235217 A CN201611235217 A CN 201611235217A CN 106692156 A CN106692156 A CN 106692156A
- Authority
- CN
- China
- Prior art keywords
- chinese
- parts
- western medicine
- allopurinol
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese and Western medicine composition for treating cirrhotic ascites. The Chinese and Western medicine composition comprises, by weight parts, 7-15 parts of aminophylline, 1-5 parts of allopurinol, 11-19 parts of l-carnitine and 3-7 parts of xanthophyll. Allopurinol and l-carnitine are mixed and ground and sieved through a 120-mesh sieve, deionized water with the mass being 3.7 times that of allopurinol and l-carnitine is added, the temperature rises to 81-83 DEG C, stirring treatment is performed for 36-39 DEG C at this temperature, and a mixture A is obtained; xanthophyll and aminophylline are placed in the mixture A, ultrasonic processing is performed for 28 min at 56 DEG C, the mixture is stirred at a temperature of 61 DEG C to be dry, and granulation is performed to obtain the Chinese and Western medicine composition. The total effective rate of the Chinese and Western medicine composition for treating cirrhotic ascites reaches over 98%, a patient's liver function can be improved, hypoproteinemia is corrected, ascites is quickly eliminated, and complications are reduced. Raw materials of the Chinese and Western medicine composition are simple and can be obtained easily, the preparation process is simple, and the Chinese and Western medicine composition is low in production cost and good in curative effect, takes effect quickly, has no toxic or side effect, and is suitable for being produced and popularized in a large scale.
Description
Technical field
The present invention relates to pharmaceutical technology field, specifically a kind of Chinese and western medicinal composition for treating cirrhotic ascites.
Background technology
Cirrhosis is clinical common chronic progressive hepatopathy, by one or more cause of disease be long-term or repeated action formed
Diffusivity hepatic lesion.It is posthepatitic cirrhosis in most of China, small part is alcoholic cirrhosis and Cirrhosis In Schistosomiasis.
There are extensive necrosis of liver cells, regeneration of remaining liver cell nodules, connective tissue proliferation and fiber in Histopathology every formation,
Cause lobuli hepatis structure to be destroyed to be formed with pseudolobuli, liver gradually deforms, is hardened and develops into cirrhosis.Early stage is due to liver generation
Repay function more by force can non-evident sympton, stage is main performance with hepatic disorder and portal hypertension, and has multisystem to be involved,
Often there are the complication such as UGB, hepatic encephalopathy, scabies secondary infection, hypersplenia, ascites, canceration in late period.Cirrhosis
Patient occurs multiple complications during patients with ascites alone diuretic therapy, seriously can induce hepatic encephalopathy because of electrolyte disturbance,
Even result in death.It is very fast that western medical treatment eliminates ascites, focus on improvement liver function, and water, sodium are increased using diuretics etc.
Discharge, promotes the regression of ascites, but easily causes water and rock-soil coupling.Chinese Herbs are slow, it is necessary to the problems such as long-term use.
The content of the invention
It is an object of the invention to provide a kind of Chinese and western medicinal composition for treating cirrhotic ascites, to solve above-mentioned background skill
The problem proposed in art.
To achieve the above object, the present invention provides following technical scheme：
A kind of Chinese and western medicinal composition for treating cirrhotic ascites, is made up of the following raw material according to weight portion：Aminophylline 7-
15 parts, Allopurinol 1-5 parts, l-cn 11-19 parts, lutein 3-7 parts.
As further scheme of the invention：The Chinese and western medicinal composition of the treatment cirrhotic ascites, by following according to weight
Measure the raw material composition of part：Aminophylline 9-13 parts, Allopurinol 2-4 parts, l-cn 13-17 parts, lutein 4-6 parts.
As further scheme of the invention：The Chinese and western medicinal composition of the treatment cirrhotic ascites, by following according to weight
Measure the raw material composition of part：11 parts of aminophylline, 3 parts of Allopurinol, 15 parts of l-cn, 5 parts of lutein.
A kind of preparation method of the Chinese and western medicinal composition for treating cirrhotic ascites, comprises the steps of：
1) by Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, adds the deionized water of the two 3.7 times of quality, so
After be warming up to 81-83 DEG C, and stir process 36-39min at such a temperature, mixture A is obtained；
2) lutein, aminophylline are inserted in mixture A, then the ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic work(
Rate is 1000W, then is stirred at a temperature of 61 DEG C to dry, granulates and obtains final product Chinese and Western medicine combination.
Application of the Chinese and Western medicine combination in the Chinese and Western medicine combination for the treatment of cirrhotic ascites is prepared.
Compared with prior art, the beneficial effects of the invention are as follows：
Cirrhotic ascites disease is treated in Chinese and Western medicine combination of the present invention under the synergy of each raw material, and total effective rate reaches
More than 98%, patient suffering can be mitigated, improve patient's liver function, Hypoproteinemia, rapid regression ascites are corrected, while reducing simultaneously
Hair disease, curative effect is better than prior art.Raw material of the present invention is simple and easy to get, preparation process is simple, easy to operate, low production cost, curative effect
Good, instant effect has no toxic side effect, non-relapse after healing, is suitable to mass produce and promotes.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Chinese and western medicinal composition for treating cirrhotic ascites, by the following original according to weight portion
Material composition：7 parts of aminophylline, 1 part of Allopurinol, 11 parts of l-cn, 3 parts of lutein.
By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, then
81 DEG C, and stir process 36min at such a temperature are warming up to, mixture A is obtained.Lutein, aminophylline are inserted into mixture A
In, the then ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is 1000W, then is stirred at a temperature of 61 DEG C to dry,
Granulation obtains final product Chinese and Western medicine combination.
Embodiment 2
In the embodiment of the present invention, a kind of Chinese and western medicinal composition for treating cirrhotic ascites, by the following original according to weight portion
Material composition：15 parts of aminophylline, 5 parts of Allopurinol, 19 parts of l-cn, 7 parts of lutein.
By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, then
83 DEG C, and stir process 39min at such a temperature are warming up to, mixture A is obtained.Lutein, aminophylline are inserted into mixture A
In, the then ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is 1000W, then is stirred at a temperature of 61 DEG C to dry,
Granulation obtains final product Chinese and Western medicine combination.
Embodiment 3
In the embodiment of the present invention, a kind of Chinese and western medicinal composition for treating cirrhotic ascites, by the following original according to weight portion
Material composition：9 parts of aminophylline, 2 parts of Allopurinol, 13 parts of l-cn, 4 parts of lutein.
By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, then
82 DEG C, and stir process 37min at such a temperature are warming up to, mixture A is obtained.Lutein, aminophylline are inserted into mixture A
In, the then ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is 1000W, then is stirred at a temperature of 61 DEG C to dry,
Granulation obtains final product Chinese and Western medicine combination.
Embodiment 4
In the embodiment of the present invention, a kind of Chinese and western medicinal composition for treating cirrhotic ascites, by the following original according to weight portion
Material composition：13 parts of aminophylline, 4 parts of Allopurinol, 17 parts of l-cn, 6 parts of lutein.
By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, then
82 DEG C, and stir process 37min at such a temperature are warming up to, mixture A is obtained.Lutein, aminophylline are inserted into mixture A
In, the then ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is 1000W, then is stirred at a temperature of 61 DEG C to dry,
Granulation obtains final product Chinese and Western medicine combination.
Embodiment 5
In the embodiment of the present invention, a kind of Chinese and western medicinal composition for treating cirrhotic ascites, by the following original according to weight portion
Material composition：11 parts of aminophylline, 3 parts of Allopurinol, 15 parts of l-cn, 5 parts of lutein.
By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, then
82 DEG C, and stir process 37min at such a temperature are warming up to, mixture A is obtained.Lutein, aminophylline are inserted into mixture A
In, the then ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is 1000W, then is stirred at a temperature of 61 DEG C to dry,
Granulation obtains final product Chinese and Western medicine combination.
Comparative example 1
In addition to lutein is not contained, its formula and preparation process are consistent with embodiment 5.
Comparative example 2
Only contain lutein, its preparation process is consistent with embodiment 5.
The toxicity test of embodiment 6
1) acute toxicity testing：
Using NIH mouse 60, SPF grades, male and female half and half, 18~22g of body weight carries out acute toxicity test.Mouse is random
It is divided into two groups, every group 30, i.e. control group and administration group, fasting 12 hours before experiment；In prepared by embodiments of the invention 5
Western medicine combination is dissolved in water, (concentration be 6.58g crude drugs/ml, maximum concentration) gavage, and gavage volume is 5ml/kg (i.e. singles
Dosage is 32.9 crude drugs/kg), control group gives normal saline, is administered 2 times within one day, delivery time 6 hours,
Continuous Observation 14 days after administration, and record the toxic reaction and death toll of mouse.Test result indicate that：Compare with control group,
Mouse has no notable difference after administration, tests Continuous Observation 14 days, and mouse systemic situation, diet, drinking-water, body weight increase are just
Often.32.9 crude drugs of Mouse oral gavage Chinese and Western medicine of the invention combination LD50 ＞/kg, daily maximum dosage-feeding be 65.8 crude drugs/
Kg/ days.Chinese medicine clinical application amount of the invention is 1.5g crude drugs/day/people, and in terms of 60kg, average dosage is adult's body weight
0.025g crude drugs/kg/ days.By batheroom scale：It is resistance to that mouse (average weight is in terms of 20g) oral administration gavage Chinese and Western medicine of the invention is combined
By 1316 times that amount is quantity.Therefore Chinese and Western medicine combination acute toxicity of the invention is low, clinical application safety.
2) long term toxicity test：
The Chinese and Western medicine combination of the embodiment of the present invention 5 presses 10.78,20.35 and 33.48g crude drugs/kg continuous uses 15 to mouse
After all (1.0ml/100g body weight, daily 2 times) and drug withdrawal 3 weeks, as a result show：Chinese and Western medicine of the present invention combination to the hair of rat,
The indexs such as behavior, stool and urine, body weight, organ weights, blood picture, hepatic and renal function, blood sugar, blood fat have no significant effect, and internal organs are visually
Without find difference change and histological indications show, medication 15 weeks and be discontinued 3 weeks after, each internal organs of rat nothing substantially change
Become.Chinese and Western medicine combination of the present invention is illustrated to small toxicity after rat long-term prescription, also without abnormal reaction after drug withdrawal, using safety.
Therapy study of the Chinese and Western medicine of the present invention of embodiment 7 combination to hardening patients with ascites
400 patients with cirrhosis ascites, make a definite diagnosis through ultrasound, liver function test, CT examination, exclude liver cancer, hepatic encephalopathy,
The severe complication person such as tubercular peritonitis, UGB, ascites routine test meets omission timber diagnostic criteria.All trouble
Person's liver function exists abnormal in various degree.Patient is mainly shown as that Abdeminal pain is uncomfortable, and the whole body is weak, and oliguresis is thirsty, complexion
Dark and gloomy, breathing slightly promotees double pulmonary respiration sounds clearly, and the rhythm of the heart is neat, shifting dullness (+), edema of lower extremity (++).Simple ascites 150,
Ascites is with anasarca person 300.It is classified as 8 groups, i.e. 1 group of embodiment, 2 groups of embodiment, 3 groups of embodiment, embodiment 4 at random
Group, 5 groups of embodiment, 1 group of comparative example, 2 groups of comparative example, 3 groups of comparative example.The each group course of disease 3 months~6 years, average course of disease 4.7 years.
Each group patient compares in physical data such as age, sex, the courses of disease, through statistical analysis, not statistically significant (P>0.05), have
Comparativity.
All patients using lying up, limit excessive water and sodium salt take the photograph people, maintenance water-electrolyte balance, deactivation has
Damage Chinese and Western medicine combination of liver function etc..
1 group of embodiment is combined using the Chinese and Western medicine of embodiment 1, and daily 2g twice daily takes.2 groups of embodiment is using implementation
The Chinese and Western medicine of example 2 is combined, and daily 2g twice daily takes.3 groups of embodiment is combined using the Chinese and Western medicine of embodiment 3, daily 2g, daily
Take twice.4 groups of embodiment is combined using the Chinese and Western medicine of embodiment 4, and daily 2g twice daily takes.5 groups of embodiment is using implementation
The Chinese and Western medicine of example 5 is combined, and daily 2g twice daily takes.1 group of comparative example is combined using the Chinese and Western medicine of comparative example 1, daily 2g, daily
Take twice.2 groups of comparative example is combined using the Chinese and Western medicine of comparative example 2, and daily 2g twice daily takes.3 groups of comparative example is given in spiral shell
Ester (40-100mg/d) and frusemide (10~40mg/d of frusemide) use in conjunction.Each group, for 1 course for the treatment of, is continuously controlled with two weeks
Treat 2 courses for the treatment of.Periodic review B ultrasonic and liver function.
Curative effect determinate standard：
Cure：Clinical symptoms and sign disappear, and liver function recovery is normal, and ultrasound diagnosis is normal.
Effectively：Symptom, sign improve, abdominal distension substantially mitigates, alleviations of have difficulty in breathing, ascites reduce, B ultrasonic point out ascites reduction
>50%, urine volume, abdominal circumference improves earlier above；Laboratory examination makes moderate progress, and liver function is normal.
It is invalid：Ascites has no mitigation, or even increases, and other symptoms and liver function do not recover normal.
Table 1
Liver function index change before and after 5 groups of 2 embodiment of table and 3 groups of treatments of comparative example
5 groups of 3 embodiment of table compares with 3 groups of patient's ascites regression times of comparative example
| Group | Number of cases | Disappear within 2 weeks | Disappear in 2-4 weeks | Regression more than 50% at 4 weeks | Regression less than 50% at 4 weeks |
| 3 groups of comparative example | 50 | 5 | 15 | 16 | 14 |
| 5 groups of embodiment | 50 | 36 | 14 | 0 | 0 |
Model case
1. Lee, male, 28 years old, suffering from liver cirrhosis ascites, and sb.'s illness took a favorable turn in one week to take the combination of the Chinese and Western medicine of embodiment 5, is fullyed recover from an illness after 2 weeks
More, follow-up 1 year is without recurrence.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of Chinese and western medicinal composition for treating cirrhotic ascites, it is characterised in that be made up of the following raw material according to weight portion：
Aminophylline 7-15 parts, Allopurinol 1-5 parts, l-cn 11-19 parts, lutein 3-7 parts.
2. it is according to claim 1 treatment cirrhotic ascites Chinese and western medicinal composition, it is characterised in that by it is following according to weight
Measure the raw material composition of part：Aminophylline 9-13 parts, Allopurinol 2-4 parts, l-cn 13-17 parts, lutein 4-6 parts.
3. it is according to claim 1 treatment cirrhotic ascites Chinese and western medicinal composition, it is characterised in that by it is following according to weight
Measure the raw material composition of part：11 parts of aminophylline, 3 parts of Allopurinol, 15 parts of l-cn, 5 parts of lutein.
4. the preparation method of the Chinese and western medicinal composition of a kind for the treatment of cirrhotic ascites as described in claim 1-3 is any, it is special
Levy and be, comprise the steps of：
1）By Allopurinol and l-cn mixed grinding, 120 mesh sieves are crossed, add the deionized water of the two 3.7 times of quality, Ran Housheng
Temperature is to 81-83 DEG C, and stir process 36-39min at such a temperature, and mixture A is obtained；
2）Lutein, aminophylline are inserted in mixture A, then the ultrasonically treated 28min at a temperature of 56 DEG C, ultrasonic power is
1000W, then stirred at a temperature of 61 DEG C to dry, granulate and obtain final product Chinese and Western medicine combination.
5. the Chinese and Western medicine combination as described in claim 1-3 is any is preparing answering during treatment cirrhotic ascites Chinese and Western medicine is combined
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611235217.6A CN106692156A (en) | 2016-12-28 | 2016-12-28 | Chinese and Western medicine composition for treating cirrhotic ascites |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611235217.6A CN106692156A (en) | 2016-12-28 | 2016-12-28 | Chinese and Western medicine composition for treating cirrhotic ascites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106692156A true CN106692156A (en) | 2017-05-24 |
Family
ID=58902051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611235217.6A Pending CN106692156A (en) | 2016-12-28 | 2016-12-28 | Chinese and Western medicine composition for treating cirrhotic ascites |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692156A (en) |
-
2016
- 2016-12-28 CN CN201611235217.6A patent/CN106692156A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN105106440B (en) | A kind of Chinese medicine composition for the treatment of headache and dizzy after lumbar anesthesia | |
| CN106619697A (en) | Drug for treating cirrhosis with ascites, preparation method thereof and application | |
| CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
| CN106852932A (en) | A kind of medicine for treating cirrhotic ascites | |
| CN106389439A (en) | Chinese and western medicine composition for curing liver cirrhosis ascites, and preparation method and application thereof | |
| CN106692156A (en) | Chinese and Western medicine composition for treating cirrhotic ascites | |
| CN105233167A (en) | Medicine composition for treating vascular neuralgia headache | |
| CN103705840B (en) | A kind of pharmaceutical composition and preparation method thereof for the treatment of acute and chronic cholecystitis, cholelithiasis | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN104689239A (en) | Traditional Chinese medicine composition for treating cholelithiasis and preparation method thereof | |
| CN106580954A (en) | Drug for treating ascites due to cirrhosis and preparation method and application thereof | |
| CN107137456A (en) | It is a kind of to treat medicine of chronic osteomyelitis and its preparation method and application | |
| CN106580955A (en) | Drug for treating hepatitis C virus | |
| CN101406669B (en) | Chinese patent medicine for treating comedo and acne | |
| CN106619649A (en) | Medicine composition for treating tuberculous pleurisy, method for preparing medicine composition and application thereof | |
| CN105796952A (en) | Gliquidone-containing medicine combination for treating diabetes and preparation method thereof | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN105770205A (en) | Pharmaceutical composition containing felodipine and capable of treating hypertension and preparation method thereof | |
| CN104740013A (en) | Traditional Chinese medicine composition for treating malignant tumors | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN102961678B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| NL2031200A (en) | Composition for treating cancer and preparation method and application thereof | |
| CN111603539A (en) | Traditional Chinese medicine composition for preventing and treating gout and preparation method and application thereof | |
| CN108403838A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170524 |